EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Navigating through regulatory frameworks for digital therapeutics and biomarkers

Cinja Koller iD, Marc Blanchard iD, Thomas Hügle iD

Health Informatics Journal · 2025

DOI: 10.1177/14604582251387656 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Health Informatics Journal, 2025. Verfasst von Cinja Koller und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland. Hauptthemen laut MEDLINE: Biomarkers, Digital Technology. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Digital health technologies are often subject to regulatory requirements. Regulatory auditing processes are complex but necessary to guarantee quality, efficacy and safety of patients. Evolvements such as digitalized clinical trials, and digital biomarkers require a constant adaption of regulatory frameworks.

Objective

This review aims to provide an overview on current regulations and standards for digital therapeutics and digital biomarkers, from technical development to market access.

Methods

We conducted an unstructured literature review to identify the relevant guidelines, policies and standards for software based digital therapeutics and digital biomarkers.

Results

The principal regulations governing software as a medical device are outlined in Chapter 21 of the Code of Federal Regulations by the US Food and Drug Administration, as well as the European Medical Device Regulation 2017/745. Regulatory pathways, such as the DiGA, are in the process of development, particularly for digital therapeutics, which fall within the purview of software as a medical device. Qualification of (digital) biomarkers is typically voluntary but can play a significant role in the development and approval of digital therapeutics.

Conclusions

Fragmented, lacking and diverse regulations around digital biomarkers and digital therapeutics highlight the urge to harmonize and foster regulatory frameworks on an international level.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersDigital TechnologyHumansUnited States Food and Drug AdministrationUnited StatesSoftware

Stichwörter der Autor:innen

CFREMAFDAMDRdigital biomarkerdigital healthdigital therapeuticsregulationsoftware as a medical device

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland.

ORCID-Profile: Cinja Koller, Marc Blanchard, Thomas Hügle

Zitieren

APA

Koller, C., Blanchard, M., & Hügle, T. (2025). Navigating through regulatory frameworks for digital therapeutics and biomarkers. Health Informatics Journal. https://doi.org/10.1177/14604582251387656

Vancouver

Koller C, Blanchard M, Hügle T. Navigating through regulatory frameworks for digital therapeutics and biomarkers. Health Informatics Journal. 2025. doi:10.1177/14604582251387656

BibTeX
@article{Koller2025,
  author = {Koller, Cinja and Blanchard, Marc and Hügle, Thomas},
  title = {Navigating through regulatory frameworks for digital therapeutics and biomarkers},
  journal = {Health Informatics Journal},
  year = {2025},
  doi = {10.1177/14604582251387656}
}
Kostenlos starten →